Efficacy of single-dose galcanezumab 240 mg on episodic or refractory chronic cluster headache: prospective, 4-week, real-world evidence from the GRASP study group
A single 240 mg dose of galcanezumab significantly reduced attack frequency, pain, and duration in both patients with eCH and refractory cCH, improved quality of life and patients' satisfaction, and was well-tolerated. These real-world findings support the use of galcanezumab mostly in eCH, while larger studies are needed to clarify its role in cCH.
Authors
- Aikaterini Foska (ORCID: https://orcid.org/0000-0002-5164-4952)
- Maria Chondrogianni (ORCID: https://orcid.org/0000-0002-8315-5846)
- Dimitrios Rikos (ORCID: https://orcid.org/0000-0003-2346-5057)
- Panagiotis Soldatos
- Maria Koutsokera
- Emmanouil V. Dermitzakis (ORCID: https://orcid.org/0000-0001-9275-0076)
- Michail Vikelis
- Andreas A. Argyriou
Institutions
- National and Kapodistrian University of Athens (GR)
- Agios Andreas Hospital (GR)
- Military Hospital (PK)
- General Clinic Phương Nam (VN)
- Thriasio General Hospital of Elefsina (GR)
- University Hospital of Ioannina (GR)
- Base Training (GR)
- Ophthalmology Clinic (DE)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2026-01-12
- DOI
- https://doi.org/10.3389/fneur.2025.1748498
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00